Hair loss, explained. Explore research and treatments.
Learn
What each drug, ingredient and condition is, with the top and newest studies on each.Research
Each month's hair loss papers, summarized, with every study linked to its source.Community
Ask questions and compare regimens and results with others treating hair loss. New Featured Research
Photo‐ and Temperature‐Conditioned Versus Conventional Platelet‐Rich Plasma for Androgenetic Alopecia: A Split‐Scalp, Double‐Blind, and Randomized Active‐Comparator Trial
A split-scalp RCT in 21 AGA patients found red-light/cold-conditioned PRP no better than conventional PRP; both modestly increased hair shaft diameter.
Read MoreNew in research
-
Topical Minoxidil for Female Pattern Hair Loss: Clinical Outcomes in Postmenopausal Women
A review with phase III post hoc data found once-daily 5% minoxidil foam regrew hair in postmenopausal women regardless of FPHL severity. -
Carnosic acid–loaded nanostructured lipid carriers for targeted follicular delivery and hair regeneration in androgenetic alopecia
A carnosic acid nanocarrier gel regrew hair faster than 2% minoxidil and cut inflammatory markers more in a testosterone-induced alopecia model. -
Curcumin-Loaded Zinc-Ginsenoside MOF Microneedles Attenuate Androgen-Induced Follicular Damage and Promote Hair Regrowth
Curcumin-loaded ginsenoside-zinc microneedles blocked DHT damage and accelerated hair regrowth via Wnt/β-catenin in a mouse AGA model. -
Treatment Timing and Early Hair Regrowth in Relation to Response to Intravenous Methylprednisolone Pulse Therapy in Alopecia Areata: A Retrospective Cohort Study
In 72 alopecia areata patients, starting IV methylprednisolone within 6 months and 3-month regrowth predicted 6-month response. -
Cardiovascular Safety of Oral Minoxidil Use in Hair-Loss Patients: A Systematic Review and Meta-Analysis
A meta-analysis of 63 studies found cardiovascular events with oral minoxidil uncommon and no consistent excess risk versus comparators, though risk exceeded topical minoxidil and women appeared more susceptible; individualized monitoring research is still needed. -
Forty-Eight-Week Real-World Outcomes of Ritlecitinib in Alopecia Areata: Delayed Responses and Predictive Value of Change in SALT Score at Week 24
Real-world ritlecitinib gave SALT ≤20 in 39% of severe AA patients by week 48, with some responding only after week 24. -
Follicle-Targeted Deep Eutectic Solvent-Lipid Hybrid Nanocarriers for Phloretin against Androgenetic Alopecia
A phloretin hybrid nanocarrier stimulated dermal papilla cells, cut inflammation, and regrew hair in AGA models via Wnt/β-catenin and mTOR. -
Alopecia areata-associated white hair growth can occur independent of follicular cycling
White hair occurred in 16% of 5,155 AA patients, linked to age, autoimmunity and allergy; most regained pigment with treatment. -
Evaluating current and emerging pharmacological treatment options for men with androgenetic alopecia
A review concludes current drugs work best early and mainly preserve hair; transplantation remains the only fix where follicles are lost. -
Personalized minoxidil therapy in androgenetic alopecia: from SULT1A1 biomarkers to precision clinical management
A review explains how follicular SULT1A1 testing can predict topical minoxidil response and enable personalized treatment algorithms.